Optimizing the Discovery, Translation and Clinical Development of Safe and Effective Antigen-Specific Immune Tolerance Inducing Therapies to Treat Autoimmune Diseases.
The clinical heterogeneity of more than 80 autoimmune diseases presents a significant challenge with respect to the development of therapies designed to re-establish self-tolerance. As the first generation of antigen-specific immune tolerance therapies enters the clinic and excitement around the recent deals, partnerships, IPOs and investments reaching new heights, now is the time for an industry forum for large pharma, pioneering biotech and academia to unite.
Tackling key R&D challenges, such as antigen identification, animal model predictability, translation and clinical design, the Antigen-Specific Immune Tolerance Europe Summit is the first European centric, dedicated platform that brings key decision makers together to successfully translate ground breaking science into a novel class of therapies to treat autoimmunity.
To learn more about this event, and to register online, visit http://www.as-immunetolerance-eu.com/